Introduction
AD is a neurodegenerative disorder characterized by an abundance of Aβ peptides generated from amyloid precursor abnormal cleavage by membrane-associated secretases (Murphy and LeVine, 2010) . The development of AD pathology precedes cognitive symptoms and diagnosis by many years (Lazarczyk et al., 2012) , presenting challenges for studying early disease stages to aid in the discovery of preventive drugs.
Over the past decade numerous transgenic animal models of AD have been generated to aid in understanding mechanisms of the disease in humans (Gotz and Ittner, 2008) . However, such animals must express multiple pathological proteins at levels higher than endogenous genes to exhibit AD pathology, highlighting the value of developing complementary models to enable investigations in human cells with gene expression patterns closer to endogenous levels. In particular, in vitro models derived from hPSCs offer strong platforms for basic research and subsequent therapeutic development for early stages of AD.
Tapping into this potentially exciting new class of disease models requires efficient differentiation of hPSCs into neurons affected by AD. In particular, glutamatergic neurons are severely afflicted in the cerebral cortex, and disruption of their circuits is associated with the hallmark memory deficits of AD (Francis et al., 1993; Greenamyre et al., 1988) . In contrast, studies of human postmortem AD brain suggest that Available online on ScienceDirect (www.sciencedirect.com).
